Early detection of breast cancer return using blood tests and scans
Part of Cancer, Skin clinical trials.
This study uses a simple blood test (liquid biopsy) along with imaging scans to look for early signs that triple-negative breast cancer may have returned in patients who still had cancer after chemo. It aims to catch a possible recurrence sooner, which could help guide earlier treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have triple-negative breast cancer confirmed by a biopsy (cancer that does not have estrogen, progesterone, or HER2 receptors).
- Your cancer was stage 2 or 3 at diagnosis and was larger than 10 mm, possibly with lymph node involvement.
- After completing chemotherapy before surgery, your surgical sample still showed cancer (called 'residual disease').
- You are not pregnant, and your kidneys work well enough (based on a blood test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
This study looks at whether a blood test (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. It focuses on people with HER2-positive or triple-negative breast cancer that has not spread far.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.